<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05627752</url>
  </required_header>
  <id_info>
    <org_study_id>ZhongnanH PCa</org_study_id>
    <nct_id>NCT05627752</nct_id>
  </id_info>
  <brief_title>Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage</brief_title>
  <official_title>Docetaxel Alone or in Combination With Enzalutamide as First-line Treatment for Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone: a Single Center, Randomized, Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      New androgen pathway targeting agents (ARTA), including Abiraterone acetate, Apalutamide and&#xD;
      Enzalutamide, are approved and used in treatment of metastatic hormonal sensitive prostate&#xD;
      cancer(mHSPC). However, the development of castration-resistance prostate cancer(CRPC) is&#xD;
      only a matter of time. The use of sequential ARTAs in mCRPC showed limited benefit in&#xD;
      retrospective series and prospective trials. Therefore this sequence should be avoided&#xD;
      because of known cross resistance and the availability of chemotherapy and poly adenosine&#xD;
      diphosphate-ribose polymerase(PARP) inhibitors (if a relevant mutation is present).&#xD;
&#xD;
      Recently, a randomized controlled trial(RCT), the ABIDO-SOGUG, indicated that compared with&#xD;
      docetaxel, maintaining Abiraterone added to docetaxel in chemotherapy-naive patients who have&#xD;
      experienced cancer progression to Abiraterone treatment could not improve radiographic&#xD;
      progression-free survival or the other endpoints.However, another RCT, the PRESIDE trial,&#xD;
      indicated that in patients who had progressed on Enzalutamide, continued Enzalutamide&#xD;
      treatment in combination with docetaxel led to a significant improvement of PFS compared with&#xD;
      placebo plus docetaxel.&#xD;
&#xD;
      The aims of this trial is to assess both the efficacy and safety of docetaxel in combination&#xD;
      with Enzalutamide as first-line treatment in mCRPC patients progressed on Abiraterone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The time from the beginning of randomization to the first disease progression (that is, biochemical progression, tumor growth, or the discovery of new lesions) or death due to any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 16 months</time_frame>
    <description>Time from the beginning of randomization to death due to any reason.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Castrate Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group of Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel plus Enzalutamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group of Docetaxel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Docetaxel plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide 40 MG</intervention_name>
    <description>Adding Enzalutamide to Docetaxel chemotherapy</description>
    <arm_group_label>Group of Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel injection</intervention_name>
    <description>Docetaxel chemotherapy</description>
    <arm_group_label>Group of Combination</arm_group_label>
    <arm_group_label>Group of Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adenocarcinoma&#xD;
&#xD;
          -  mCRPC&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group(ECOG) 0-1&#xD;
&#xD;
          -  prior Abiraterone treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior Enzalutamide or Docetaxel treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhonghua Yang</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhonghua Yang, Dr.</last_name>
      <phone>86 18071118052</phone>
      <email>yangzhonghua@whu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhonghua Yang</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhonghua Yang, Dr.</last_name>
      <phone>18071118052</phone>
      <email>yangzhonghua@whu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>October 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 23, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2022</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>Enzalutamide</keyword>
  <keyword>Abiraterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

